Immune System Modulates Response to Trastuzumab, Pertuzumab

Share this content:
The immune system modulates response to therapies containing trastuzumab and pertuzumab in patients with breast cancer.
The immune system modulates response to therapies containing trastuzumab and pertuzumab in patients with breast cancer.

The immune system modulates response to therapies containing trastuzumab and pertuzumab in patients with breast cancer, a new study published online ahead of print in the journal Annals of Oncology has shown.

For the study, researchers sought to investigate in the NeoSphere trial, which evaluated the efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer, the contribution of the immune system to pathological complete response in breast (pCRB) after neoadjuvant docetaxel with trastuzumab, pertuzumab, or both, or monoclonal antibodies alone.

Results showed that the greatest benefit from neoadjuvant docetaxel with trastuzumab and pertuzumab was observed for low expression of MHC1, CTLA4, PDL1, and IF-1 immune markers.

RELATED: Women With Mucinous, Tubular/Cribriform Breast Cancer Fare Better Than Other Histotypes

Researchers found that in the combined trastuzumab/pertuzumab/monoclonal antibodies alone treatment group, higher expression of PD1, MHC2, and STAT1 were associated with pCRB.

“The involvement of PDL1 in resistance supports testing combinations of HER2-directed antibodies and immune-checkpoints inhibitors,” the authors concluded.

Reference

  1. Bianchini G, Pusztai L, Pienkowski T, et al. Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial [published online ahead of print September 19, 2015]. Ann Oncol. doi: 10.1093/annonc/mdv395.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs